PBS eases restrictions on PAH medicines to include WHO FC II patients

PBS access criteria for Pulmonary Arterial Hypertension (PAH) medicines have been eased to allow the use of ERA or PDE-5 inhibitor monotherapy in patients with WHO Functional Class (FC) II symptoms. From 1 May 2020 PAH patients with WHO FC II symptoms will be able to access PBS-subsidised monotherapy with endothelin receptor antagonist (ERA) medicines ...

Already a member?

Login to keep reading.

© 2021 the limbic